Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rawson Paz ElvirafiledCriticalRawson Paz Elvira
Publication of AR095694A4publicationCriticalpatent/AR095694A4/en
Se refiere a un profiláctico o preservativo femenino aplicable para uso vaginal como barrera física preventiva de enfermedades de transmisión sexual y anticonceptivo, el cual presenta la particularidad de estar constituido por una fina funda tubular de material específico para prevenir de un modo más efectivo el contagio de enfermedades de transmisión sexual, que además presenta medios de sujeción externos para adherirse a los labios superiores en la entrada vaginal sin que afecten ni a la uretra ni al clítoris, medios para adherirse y quedar transferido al pene de hombre tras la penetración y medios de aplicación para facilitar su colocación previa a dicha penetración, la cual, ventajosamente no ha de ser necesariamente inmediata.It refers to a female prophylactic or preservative applicable for vaginal use as a preventive physical barrier of sexually transmitted and contraceptive diseases, which has the peculiarity of being constituted by a thin tubular sheath of specific material to prevent more effectively the spread of Sexually transmitted diseases, which also presents external means of attachment to adhere to the upper lips in the vaginal entrance without affecting either the urethra or the clitoris, means to adhere and be transferred to the man's penis after penetration and means of application to facilitate its placement prior to such penetration, which, advantageously, must not necessarily be immediate.
Combination of 0.1 to 1 mg of at least one sgc stimulator selected from a defined group with 2.5 to 20 mg of a pde5 inhibitor selected from another group; Pharmaceutical formulation that includes and uses it in the treatment of male sexual dysfunction.
An inclusion complex comprising a) a cyclodextrin, b) fulvestrant and c) a carrier; its method of preparation; formulation and dosage form comprising the complex; preparation comprising the complex or formulation; and its use in the treatment of cancer and systemic lupus erythematosus, among other diseases.
Pharmaceutical composition in the form of a solution comprising apomorphine, a water-soluble co-solvent, an antioxidant and water, in which the ph is greater than 4; procedure to manufacture it; and its use as an injectable solution in the treatment of parkinson's disease.